WO2012093404A3 - Parenteral formulations of levosimendan - Google Patents

Parenteral formulations of levosimendan Download PDF

Info

Publication number
WO2012093404A3
WO2012093404A3 PCT/IN2011/000893 IN2011000893W WO2012093404A3 WO 2012093404 A3 WO2012093404 A3 WO 2012093404A3 IN 2011000893 W IN2011000893 W IN 2011000893W WO 2012093404 A3 WO2012093404 A3 WO 2012093404A3
Authority
WO
WIPO (PCT)
Prior art keywords
levosimendan
parenteral formulations
pharmaceutically acceptable
composition
solution
Prior art date
Application number
PCT/IN2011/000893
Other languages
French (fr)
Other versions
WO2012093404A8 (en
WO2012093404A2 (en
Inventor
Mafatlal Tribhovandas DAVE
Jayesh Pannalal CHOKSI
Pranav Jayesh CHOKSI
Original Assignee
Gufic Biosciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gufic Biosciences Limited filed Critical Gufic Biosciences Limited
Publication of WO2012093404A2 publication Critical patent/WO2012093404A2/en
Publication of WO2012093404A8 publication Critical patent/WO2012093404A8/en
Publication of WO2012093404A3 publication Critical patent/WO2012093404A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention discloses an alcohol and acid free pharmaceutical composition for parental administration comprising; (i) levosimendan or a pharmaceutically acceptable salt thereof as an active ingredient; (ii) 10% solution of Kollidone PF- 12 in aqueous solution as a solubilizing agent; and (iii) pharmaceutically acceptable alkalinizing or buffering agent; wherein said composition is stable at a pH in the range of 6-8.
PCT/IN2011/000893 2011-01-03 2011-12-26 Parenteral formulations of levosimendan WO2012093404A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN11MU2011 2011-01-03
IN11/MUM/2011 2011-01-03

Publications (3)

Publication Number Publication Date
WO2012093404A2 WO2012093404A2 (en) 2012-07-12
WO2012093404A8 WO2012093404A8 (en) 2012-09-20
WO2012093404A3 true WO2012093404A3 (en) 2012-11-08

Family

ID=45614871

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000893 WO2012093404A2 (en) 2011-01-03 2011-12-26 Parenteral formulations of levosimendan

Country Status (1)

Country Link
WO (1) WO2012093404A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017037737A1 (en) * 2015-09-04 2017-03-09 Gufic Biosciences Limited Parenteral formulations of levosimendan

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019334A2 (en) * 1999-09-10 2001-03-22 Orion Corporation Pharmaceutical solutions of levosimendan
WO2008082871A1 (en) * 2006-12-28 2008-07-10 Orion Corporation Formulations of levosimendan for parenteral administration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2266841A (en) 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
GB9614098D0 (en) 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019334A2 (en) * 1999-09-10 2001-03-22 Orion Corporation Pharmaceutical solutions of levosimendan
WO2008082871A1 (en) * 2006-12-28 2008-07-10 Orion Corporation Formulations of levosimendan for parenteral administration

Also Published As

Publication number Publication date
WO2012093404A8 (en) 2012-09-20
WO2012093404A2 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
WO2012054831A3 (en) Ready to use ketorolac formulations
WO2007027941A3 (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
FR2906140B1 (en) GALENIC FORM FOR TRANSMUCOSUS ADMINISTRATION OF ACTIVE INGREDIENTS
EP3626253A3 (en) Stable formulations of linaclotide
CA2757418C (en) Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
MX2009007742A (en) Multi-phasic pharmaceutical formulations of poorly water-soluble drugs for reduced fed/fasted variability and improved oral bioavailability.
AU2012243329A8 (en) 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
WO2007014124A3 (en) High drug load formulations and dosage forms
IN2014MN02213A (en)
WO2011012816A3 (en) Pharmaceutical formulation
TN2013000257A1 (en) Immunosuppressant formulations
WO2007056205A3 (en) Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
MD20150050A2 (en) Stable preservative-free mydriatic and anti-inflammatory solutions for injection
WO2007100382A3 (en) Orally administrable gallium compositions and method of use
WO2009016498A8 (en) Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
EA201291089A1 (en) METHOD FOR OBTAINING PHARMACEUTICAL PREPARATIONS INTENDED FOR ORAL ADMINISTRATION, CONTAINING ONE OR MORE ACTIVE INGREDIENTS AND CONTAINING COMPOSITIONS
MY155938A (en) Oral pharmaceutical composition
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
WO2009007137A3 (en) Pharmaceutical composition for topical application of poorly soluble compounds
WO2011016049A3 (en) A stable composition of ready-to-use gemcitabine injection
MX2012013872A (en) Oral dosage forms of bendamustine.
WO2009084041A3 (en) Pharmaceutical compositions of dexibuprofen
WO2009084036A3 (en) Composition for treatment of viral infections
WO2007065625A3 (en) Pharmaceutical compositions of short-acting hypnotic agents in modified-release forms and the procedures to prepare the mentioned formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11818954

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11818954

Country of ref document: EP

Kind code of ref document: A2